Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
Date:7/28/2009

X1032 from the European Medicines Agency.
  • Lexicon completed the multiple ascending-dose portion of a Phase 1 study of its LX4211 drug candidate to evaluate the safety, tolerability, and pharmacokinetics of LX4211 in healthy volunteers over a seven-day dosing period. Top-line results from the Phase 1 clinical trial will be available later this quarter.
  • Lexicon is preparing to initiate a Phase 2a study of LX2931 in patients with rheumatoid arthritis. Lexicon has identified the clinical trial sites for the Phase 2 study, and patient enrollment is expected to begin in the third quarter of 2009. In addition, Lexicon presented Phase 1 data for LX2931 at the European League Against Rheumatism (EULAR) annual meeting on June 13, 2009.
  • Lexicon continues to enroll patients in a Phase 2a clinical trial of its LX1031 drug candidate for non-constipating irritable bowel syndrome (IBS). Enrollment is on track to be completed by year-end. The trial is designed as a double-blind, randomized, placebo-controlled study to evaluate the safety and tolerability of LX1031 and its effects on symptoms associated with IBS. In addition, Lexicon presented Phase 1 data for LX1031 at the Digestive Disease Week (DDW) annual meeting on May 31, 2009.
  • Ajay Bansal, formerly of Tercica, Inc., was appointed executive vice president of corporate development and chief financial officer, responsible for leading the compa
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine news :

    1. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
    2. Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research
    3. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
    4. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
    5. Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
    6. Hisamitsu Pharmaceutical Co., Inc. Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals, Inc.
    7. Webcast Alert: Isis Pharmaceuticals Second Quarter 2009 Financial Results Conference Call
    8. UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
    9. Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
    10. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
    11. EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk ... trendy items. Recently, the company has unveiled its 2014 ... and elegant wedding gowns, Angeldress.co.uk wants to make sure ... an easy way. Its high quality vintage wedding outfits ... off to 62% off. , Online shopping is becoming ...
    (Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide Headaches’ ... resolve,” said Steve Young of Ew Publishing; “I’ve had ... that is more intense.” , “It should be a ... migraines, that medical research is pointing to some relief ... , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical found ...
    (Date:9/21/2014)... C8 lawsuits move forward in the U.S. District ... 20 possible C8 lawsuits selected for bellwether trials ... & Schulte LLC. Court records show these six C8 ... filed that represent individuals who purportedly developed kidney cancer, ... being exposed to water contaminated by the C8 chemical ...
    (Date:9/20/2014)... Recently, UWDress.com, a professional company of women’s dresses and ... announced evening cocktail dresses . As a matter ... are very popular among worldwide customers. Now, all its ... to 65 percent off). , All UWDress.com’s employees ... outfits for the global clients. The company is famous ...
    (Date:9/20/2014)... GA (PRWEB) September 20, 2014 David ... 20, 2014. The first poster looked at the clinical ... cardiac cycle for calculating diastolic function. In conjunction with ... end-stage renal disease and normal LVEF by echo (>50%). ... stress protocol, and standard SPECT. Emory Toolbox 4.0 ...
    Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3
    ... Electronic devices of the future could be smaller, faster, ... discovery by researchers at the Department of Energy,s Oak ... published in Science , involves a method to ... decades have held tremendous promise but have eluded experimental ...
    ... 17 HealthTronics, Inc. ("HealthTronics") (Nasdaq: HTRN ... ) announced today that HealthTronics has commenced an exchange ... common stock pursuant to their previously-announced definitive agreement dated ... of the exchange offer, Endocare stockholders who validly tender ...
    ... Inclusion of General Surgeons, Otolaryngologists and , Ophthalmologists ... The American College of Surgeons (ACS) supports legislation ... Zack Space (D-Ohio), which includes the participation of general ... Loan Repayment Program called the Access to Frontline Health ...
    ... AMERIGROUP Corporation (NYSE: AGP ) today announced that it ... June 24 in Boston, Massachusetts. , , A live webcast ... p.m. Eastern Time, can be accessed on AMERIGROUP,s Web site, ... of the webcast will be available for 30 days after the ...
    ... ... Center, the most comprehensive program in Orange County. Hoag Voice and Swallowing Center provides ... , ... CA (Vocus) June 17, 2009 -- Hoag Hospital announces the grand opening of ...
    ... Health-privacy advocates and patient-choice supporters will discuss implications of federal ... on Thursday, June 18 at 9:00 am. Health-policy experts will ... HEALTH-PRIVACY RIGHTS: Which bills will make sure Americans are not ... and track them from cradle to grave and that citizens ...
    Cached Medicine News:Health News:ORNL finding could help electronics industry enter new phase 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 3Health News:American College of Surgeons Supports Bill to Create New Frontline Providers Loan Repayment Program 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 3
    (Date:9/19/2014)... 19, 2014 According to ... (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, ... & Rotary) & Geography - Global Trends & ... segments the lyophilization market on the basis of ... projections of the market size of each of ...
    (Date:9/19/2014)... 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... marketed as XIAFLEX ® in the U.S. and XIAPEX ... Tom Wegman , will present a corporate overview at ... Industry Conference. The presentation will take place ... the Millennium Broadway Hotel in New York, NY ...
    (Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
    Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
    ... Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically Meaningful ... an 88 Percent Reduction in the Risk of Cardiac ... data presented today from Abbott ,s ( NYSE: ... clinical advantages of the XIENCE V(R) Everolimus Eluting Coronary ...
    ... Boston Scientific Corporation (NYSE: BSX ) today ... of life outcomes, based on one-year data from its ... the overall cost effectiveness of percutaneous coronary intervention (PCI) ... to patient characteristics, PCI was more cost effective than ...
    Cached Medicine Technology:Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years 2Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years 3Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years 4Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years 5SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 5
    The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
    The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
    Dual offset femoral stems, hip stems that provide unique and competitive features....
    Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
    Medicine Products: